Beatriz Alvaro Mercadal

Beatriz Alvaro Mercadal

Auto-generated profile, based on publicly available information

Beatriz Alvaro Mercadal

A Department of Gynecology, Obstetrics and Reproductive Medicine , Hospital Universitari Dexeus , Barcelona , Spain

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2010 in Human Reproduction
Verified
Journal Article
Closed access
PDF file
DTD. Tiotiu
D. Tiotiu
BMB. Alvaro Mercadal
B. Alvaro Mercadal
RIR. Imbert
R. Imbert
JVJ. Verbist
J. Verbist
IDIsabelle Demeestere
Isabelle Demeestere
ADAnne Delbaere
Anne Delbaere
BACKGROUND Bone morphogenetic protein 15 (BMP15) is an oocyte-derived growth factor acting as a major player in follicle differentiation in mammals. Mutations in the BMP15 gene, some of which lead to defective secretion of bioactive dimers, have been associated with premature ovarian failure (POF) in humans.

6 March 2015 in Human Reproduction
Verified
Journal Article
Open access
PDF file
BMB. Alvaro Mercadal
B. Alvaro Mercadal
RIR. Imbert
R. Imbert
IDIsabelle Demeestere
Isabelle Demeestere
CGC. Gervy
C. Gervy
ALA. De Leener
A. De Leener
ADA. Delbaere
A. Delbaere
Could anti-Müllerian hormone (AMH) mutations be implicated in the development of idiopathic premature ovarian insufficiency (POI)? Three rare or unknown missense variants of the AMH gene were identified in a cohort of 55 POI patients; all three variants showed a drastically reduced in vitro bioactivity. Genetic factors are implicated in 5–15% of cases of POI. However, only a few genes have been shown to be involved in its development. AMH inhibits the recruitment of primordial follicles in the ovary and defective or absent AMH leads to premature depletion of the primordial follicle pool in AMH null mice. The whole coding sequence and the exon–intron junction of the AMH gene was sequenced in a cohort of 55 POI patients recruited over a period of 8 years. The studied variants were also sequenced in 197 ethnically matched controls. POI was defined as amenorrhea of more than 4 months with increased FSH before the age of 40. Patients with POI resulting from radio- or chemotherapy, surgery, chromosomal anomalies or FMR1 gene pre-mutation were excluded from the study. Recombinant human wild-type (wt) and mutated AMH proteins were produced in HEK293 T cells. KK-1 cells transfected with the AMH receptor type 2 (AMHR2) and a BMP responsive element coupled to a luciferase reporter vector were stimulated with different concentrations of wt AMH and the three tested variants. The whole coding sequence of the AMH gene could be performed and analyzed for 50 POI patients: 16 variants were found, including 6 missense variants from which 1 was unknown (R444H) and 2 were very rare (G264R and D288E). The variant D288E was also found in one of the patient's mother who also underwent POI at 32 years old. The stimulation of the AMHR2 assessed by the luciferase activity was drastically reduced for the three variants when compared with the wt AMH. The study is limited by a relatively small number of patients in the POI cohort. This is the first time that the bioactivity of AMH variants related to POI patients is tested in vitro. The functional study showed a drastic reduction of the protein activity for the three variants, supporting their contribution to the development of the ovarian insufficiency. The familial segregation further supports the implication of AMH in the development of POI. The study was performed thanks to funding from the ‘Fondation Erasme’. No conflicts of interest are declared.

6 June 2011 in Human Reproduction
Verified
Journal Article
Open access
PDF file
BMB. Alvaro Mercadal
B. Alvaro Mercadal
RIR. Imbert
R. Imbert
IDIsabelle Demeestere
Isabelle Demeestere
YEY. Englert
Y. Englert
ADA. Delbaere
A. Delbaere
Fertility expectations for patients with Turner's syndrome (TS) have clearly changed in the last three decades. However, medical risks during pregnancy are supposed to be highly increased. The aim of the study was to assess clinical outcome and obstetrical complications in a series of patients with TS in an oocyte donor programme. A retrospective study was carried out on 24 women with TS seeking a pregnancy in the Fertility Clinic of the Erasme Hospital from 1992 up until March 2011. Twenty-three patients with TS were included in an oocyte donation cycle. Forty-nine oocyte donation cycles were performed, which led to 45 fresh and 10 frozen-thawed embryo transfers. Altogether, 18 pregnancies were obtained, 10 deliveries (9 singletons and 1 pair of twins), 3 miscarriages and 5 biochemical pregnancies. The clinical pregnancy rate per transfer was 24.4% in fresh cycles and 20% in frozen replacement cycles. Complications of pregnancy occurred in 5 of 10 pregnancies (50%), which led to three premature deliveries because of pregnancy-induced hypertensive disorders. The mean birthweight (g) (±SD) for singletons and twins was 2728 ± 577 and 2335 ± 318, respectively. Four babies were below the 10th percentile. No cardiac complications were observed in any of the pregnant women. Pregnancy rates after oocyte donation in patients with TS are comparable with those previously published but a high risk of pregnancy hypertensive disorders and a high risk of low birthweight can be highlighted from our study. Strict inclusion criteria and single embryo transfer are necessary to minimize complications during pregnancy in this high-risk group.

1 January 2017 in Reproductive BioMedicine Online
Verified
Journal Article
Closed access
TTTheoni B. Tarlatzi
Theoni B. Tarlatzi
RIRomain Imbert
Romain Imbert
BMBeatriz Alvaro Mercadal
Beatriz Alvaro Mercadal
IDIsabelle Demeestere
Isabelle Demeestere
CVChristos A. Venetis
Christos A. Venetis
ADAnne Delbaere
Anne Delbaere

3 September 2017 in Gynecological Endocrinology
Verified
Journal Article
Closed access
BMBeatriz Alvaro Mercadal
Beatriz Alvaro Mercadal
IRIgnacio Rodriguez
Ignacio Rodriguez
GAGemma Arroyo
Gemma Arroyo
FMFrancisca Martínez
Francisca Martínez
PBPedro Nolasco Barri
Pedro Nolasco Barri
BCBuenaventura Coroleu
Buenaventura Coroleu
The number of oocytes retrieved in in vitro fertilization (IVF) cycles is an independent factor influencing pregnancy rate (PR), and optimal number of oocytes would be between 10 and 15. This has led to the hypothesis that the identification of a suboptimal group of responders beforehand (4-9 oocytes retrieved) would allow physicians to optimize their PR. A retrospective observational study counting on 735 women doing an IVF treatment in our center was performed. Multivariable logistic regression was used to analyze the relationship between anti-Mullerian hormone (AMH) and antral follicle count (AFC), within suboptimal and optimal responders. We also analyzed the outcome of those patients with an estimated high probability of having an optimal response and the second cycles of those who did not get pregnant in the first cycle to observe the main significant traits that made them change from one group of responders to the other. Main results are that suboptimal responders account for almost half of our patients. Ovarian reserve markers (AMH and AFC) are significantly different in optimal and suboptimal responders, even when adjusted by age. There is a significant difference in the cumulative PR between both groups. Interestingly, 18.9% shifted from suboptimal to optimal response, and 36.9% from optimal to suboptimal.